Tag: G-CSF market

  • Growth Opportunities and Trends in the G-CSF (Granulocyte Colony Stimulating Factors) Market: Key Insights for 2025-2034

    Growth Opportunities and Trends in the G-CSF (Granulocyte Colony Stimulating Factors) Market: Key Insights for 2025-2034

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What fueled the previous growth in the g-csf (granulocyte colony stimulating factors) market?

    The market for G-CSF (granulocyte colony stimulating factors) has consistently expanded over the past few years. It’s projected to rise from $5.5 billion in 2024 to $5.72 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.9%. Factors contributing to this growth during the historic period include a rise in cancer incidence, robust economic development in emerging markets, escalated spending on healthcare, an upsurge in pharmaceutical research & development expenditure, and government initiatives.

    What will be the g-csf (granulocyte colony stimulating factors) market size in the future?

    The geopolymer market is slated to experience substantial expansion in the upcoming years, reaching a staggering $41.71 billion by 2029 with a compound annual growth rate (CAGR) of 28.2%. Influences driving this growth during the forecast period are expected to be advancements in the construction sector, improvements in production methods, widespread urbanization and infrastructure projects, along with increased partnerships within the industry and dedication to innovation. Key trends to look out for during the forecast period encompass the use of geopolymers in eco-friendly packaging, its integration within the aerospace industry, initiatives towards standardization and certification, geopolymer concrete usage in earthquake-prone regions and market broadening in evolving economies.

    Get your g-csf (granulocyte colony stimulating factors) market report here!

    https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

    What main drivers are fueling expansion in the g-csf (granulocyte colony stimulating factors) market?

    One significant driver of growth in the G-CSF (granulocyte colony stimulating factor) market is the escalating occurrence of cancer. Globally, cancer consistently ranks as the second most common cause of death, with one in six fatalities attributed to it. For example, data from the American Cancer Society, a US-based organization committed to eradicating cancer, indicates that January 2023 will see an estimated 1,958,310 new cancer diagnoses and 609,820 cancer-related deaths in the United States. G-CSF represents a category of growth factors instrumental in generating white blood cells in the bone marrow, thereby lessening the potential for infection and sepsis. It considerably aids in the recovery of cancer patients and lowers the mortality rate ensuing from chemotherapy-induced neutropenia. Moreover, it has proven effective in curtailing infections after specific cancer treatments. Consequently, the mounting incidence of cancer will likely propel the expansion of the G-CSF market.

    What key areas define the segmentation of the global g-csf (granulocyte colony stimulating factors) market?

    The G-CSF (granulocyte colony stimulating factors) market covered in this report is segmented –

    1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

    2) By Product: Tablet, Capsule, Other Products

    3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

    Subsegments:

    1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

    2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

    3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

    4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

    Who are the dominant players expanding their reach in the g-csf (granulocyte colony stimulating factors) market?

    Major companies operating in the G-CSF (granulocyte colony stimulating factors) market include Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, BeyondSpring Inc., Kyowa Hakko Kirin Co. Ltd, BioCad, Stada Arzneimittel, Dong-A Socio Group, Dr. Reddy’s Laboratories, Celltrion Inc., Emcure Pharmaceuticals, Accord Healthcare UK, Intas Pharmaceuticals, Spectrum Pharmaceuticals, Apobiologix, Apotex Inc., Eurofarma Laboratórios, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline plc, AstraZeneca, Merck Sharp & Dohme Corp., Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Cipla.

    How are evolving market trends shaping g-csf (granulocyte colony stimulating factors) Strategies?

    In the G-CSF (granulocyte colony stimulating factor) market, companies are zeroing in on strategic partnerships to develop novel products and expand their market presence. Collaborations with other companies, educational institutions, and research bodies have seen an uptick in recent years, often through in or out-licensing agreements. For instance, in 2022, Singapore’s Evive Biotech established an exclusive long-term licensing deal with APOGEPHA, a German pharmaceutical firm, for the sale of Efbemalenograstim alfa (F-627) in Germany and Switzerland. F-627 is an innovative G-CSF long-acting fusion protein that does not require pegylation.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3466

    Which regions are emerging as leaders in the g-csf (granulocyte colony stimulating factors) market?

    North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2024. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    Browse Through More Similar Reports By The Business Research Company:

    Colorectal Cancer Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

    Thyroid Cancer Drugs Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

    Hematology Analyzers and Reagents Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/hematology-analyzers-and-reagents-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Key Trends and Insights into the G-CSF (Granulocyte Colony Stimulating Factors) Market: Growth Rate and Opportunities to 2034

    Key Trends and Insights into the G-CSF (Granulocyte Colony Stimulating Factors) Market: Growth Rate and Opportunities to 2034

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What Future CAGR is Anticipated for the G-CSF (Granulocyte Colony Stimulating Factors) Market Over the 2025–2034 Period?

    The G-CSF (granulocyte colony stimulating factors) market has seen steady growth in recent years. It is expected to grow from $5.5 billion in 2025 to $5.72 billion in 2025, at a CAGR of 3.9%. Key factors include rising cancer prevalence, increased healthcare spending, higher pharmaceutical R&D expenditure, and government initiatives.

    The G-CSF (granulocyte colony-stimulating factors) market is projected to reach $7.19 billion by 2029 at a CAGR of 5.9%. The growth is attributed to the increasing prevalence of cancer, higher demand for prophylaxis G-CSF, advancements in technology, and the growing penetration of biosimilars. Trends include extensive R&D investments, strategic mergers and acquisitions, and a focus on biosimilar production for neutropenia treatment.

    Which Drivers Are Expected to Have the Greatest Impact on the g-csf (granulocyte colony stimulating factors) Market’s Growth?

    The increasing prevalence of cancer is expected to drive the growth of the G-CSF market. Cancer is the second leading cause of death, and G-CSF helps improve recovery for cancer patients undergoing chemotherapy. For example, the American Cancer Society projected 1.9 million new cancer cases in the U.S. in 2023. The rising cancer prevalence is fueling the demand for G-CSF treatments.

    Get Your Free Sample of the Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

    Who Are the Influential Players Fueling Innovation and Growth in the G-CSF (Granulocyte Colony Stimulating Factors) Market?

    Major companies operating in the G-CSF (granulocyte colony stimulating factors) market include:

    • Amgen Inc._x000D_

    • Coherus Biosciences Inc._x000D_

    • Sandoz_x000D_

    • Biocon/Mylan_x000D_

    • Teva Pharmaceuticals Inc._x000D_

    What Impact Are Industry Trends Having on the G-CSF (Granulocyte Colony Stimulating Factors) Market’s Future Prospects?

    Companies in the G-CSF market are focusing on strategic collaborations to expand their market share. For instance, in 2022, Evive Biotech, a Singapore-based biopharmaceutical company, partnered with APOGEPHA, a German pharmaceutical firm, to commercialize a novel G-CSF protein in Germany and Switzerland.

    Get Instant Access to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report with Swift Delivery!

    https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

    What Are the Major Categories and Their Growth Dynamics in the G-CSF (Granulocyte Colony Stimulating Factors) Market?

    The G-CSF (granulocyte colony stimulating factors) market covered in this report is segmented –

    1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

    2) By Product: Tablet, Capsule, Other Products

    3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

    Subsegments:

    1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

    2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

    3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

    4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

    What Regions Are Leading the Growth Trajectory of the G-CSF (Granulocyte Colony Stimulating Factors) Market?

    North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the G-CS (granulocyte colony stimulating factors) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    What Are the Key Characteristics That Define the G-CSF (Granulocyte Colony Stimulating Factors) Market?

    G-CSF (granulocyte colony stimulating factors) refers to a type of colony-stimulating factor that aids in the bone marrow’s ability to produce more white blood cells. Patients who have specific tumors, neutropenia brought on by some types of chemotherapy, or severe persistent neutropenia unrelated to cancer treatment are all treated with G-CSF. Filgrastim and Granulocyte Colony-Stimulating Factor are other names for it.

    Browse Through More Similar Reports By The Business Research Company:

    Colorectal Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

    Thyroid Cancer Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

    Hematology Analyzers and Reagents Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/hematology-analyzers-and-reagents-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on: